Peptides for Bodybuilding: What Works, What Doesn't, and What's Safe

Key Takeaways

• Compounds covered: CJC-1295, ipamorelin, sermorelin, MK-677, BPC-157, TB-500
• Goal area: Body composition, lean mass support, and training recovery
• Evidence range: Ranges from Phase II RCTs in older adults and GH-deficient populations (MK-677, CJC-1295) to animal-only data (BPC-157, TB-500)
• Regulatory range: Historically compoundable under Section 503A for limited clinical off-label use (CJC-1295, ipamorelin, sermorelin — all three with 503A availability contracting following the April 22, 2026 PCAC action); and research-only compounds with 503A compounding effectively prohibited (BPC-157, TB-500) or never available through 503A (MK-677)
• Key biomarkers for bodybuilding context: IGF-1, fasting glucose, HbA1c, hs-CRP, total testosterone, comprehensive metabolic panel
• As of April 22, 2026: GH-releasing peptides including ipamorelin, CJC-1295, and MK-677 are WADA-prohibited substances; BPC-157 and TB-500 were removed from FDA's Category 2 list and are outside any FDA-permissible compounding category.
• Bottom line: No peptide discussed in bodybuilding contexts has been studied in healthy resistance-trained athletes for performance or hypertrophy outcomes — all human evidence is from clinical populations with GH deficiency or age-related decline.

This article takes the bodybuilding peptide landscape on its own terms — which compounds are circulating, what the actual evidence shows, and where the genuine gaps between claimed effects and clinical data exist. The goal is not to dismiss the mechanisms, which are real, but to give each compound an accurate evidence label so the distinction between "studied" and "proven" is visible.

Understanding Body Composition in Bodybuilding: The Biology

Bodybuilding is essentially applied body composition biology: increasing lean mass (skeletal muscle hypertrophy) while minimizing fat mass. At the molecular level, this requires sustained positive muscle protein balance — driven by resistance training load, sufficient protein intake, and adequate anabolic hormonal signaling — alongside effective recovery from training-induced tissue stress.

Peptides enter this context through two axes. The GH/IGF-1 axis is the primary anabolic signaling system independent of testosterone. Growth hormone, secreted by the pituitary in pulsatile bursts during sleep and post-exercise, drives hepatic IGF-1 production. IGF-1 activates the PI3K/Akt/mTOR pathway in skeletal muscle, a pathway that regulates protein synthesis and, through FoxO-mediated pathways, protein breakdown — though pharmacologically elevating IGF-1 does not necessarily translate to additional hypertrophy in trained individuals (see West and Phillips, 2012, cited below). Kraemer and Ratamess, in their foundational 2005 review of hormonal responses to resistance exercise in Sports Medicine, established that GH, testosterone, and IGF-1 are the three primary anabolic hormones responding to resistance training, with GH pulses peaking 30 to 40 minutes post-exercise in high-volume training. GH secretagogues target this axis by stimulating pituitary GH release.

The second axis is tissue repair and recovery biology. Training-induced muscle damage and connective tissue stress require satellite cell activation, angiogenesis, and extracellular matrix remodeling for complete repair between sessions. Peptides studied in tissue-repair contexts — BPC-157 and thymosin beta-4 (the parent compound of TB-500) — interact with the vascular remodeling and fibroblast activation components of this biology. Their relevance to bodybuilding is as recovery-support compounds, not direct muscle-building agents.

Somatopause — the gradual decline in GH secretion beginning in the third decade — is frequently cited in discussions of GH secretagogue therapy for aging adults, though no GH secretagogue is FDA-approved for somatopause or age-related GH decline. Clinical use in this context is off-label and requires evaluation of genuine GH-axis insufficiency by a licensed provider. In younger, healthy bodybuilders with intact GH/IGF-1 axis function, the rationale is less established and the evidence is minimal.

Peptides Discussed in Bodybuilding Contexts: A Quick Comparison

The following compounds have published evidence relevant to body composition or recovery, or are widely discussed in bodybuilding communities. They are listed by strength of clinical evidence.

• Compound: MK-677 (ibutamoren)
  Mechanism for bodybuilding: Oral GH secretagogue (non-peptide small molecule); elevates GH and IGF-1 by activating ghrelin receptors; preserves fat-free mass in GH-deficient aging adults
  Evidence: Phase II RCT (Nass et al., N=65, 2-year study in adults 60–81; Svensson et al., N=24, 2 months in obese adults)
  FDA status: Not FDA-approved for any indication. MK-677 is not a peptide — it is a small-molecule ghrelin receptor agonist. FDA has treated MK-677 as an unapproved new drug and issued warning letters to online sellers marketing it for human use. It is not on the 503A Bulks List, and 503A compounding of MK-677 is not an authorized pathway.
  SP availability: Not currently available through Superpower
  WADA status: Prohibited under Section S2 of the 2026 WADA Prohibited List
  Route: Oral
• Compound: CJC-1295 / Ipamorelin
  Mechanism for bodybuilding: GHRH analog (CJC-1295) + selective GHRP (ipamorelin); combined stimulation of pulsatile GH release; short-acting formulations preserve more of the hypothalamic-pituitary feedback architecture than exogenous HGH, with long-acting DAC-modified CJC-1295 producing a more sustained GH elevation profile
  Evidence: Phase I pharmacokinetics/pharmacodynamics (Teichman et al., N=44; Raun et al., 1998 selectivity characterization)
  FDA status: Not FDA-approved. Historically compounded by 503A pharmacies; at its April 22, 2026 PCAC meeting, PCAC recommended against including CJC-1295 and ipamorelin on the 503A Bulks List, and 503A availability is actively contracting.
  SP availability: Not currently available through Superpower
  WADA status: Prohibited under Section S2 of the 2026 WADA Prohibited List
  Route: Subcutaneous injection
• Compound: Sermorelin
  Mechanism for bodybuilding: GHRH analog (29 amino acids of endogenous GHRH); stimulates pituitary GH release with preservation of hypothalamic-pituitary feedback
  Evidence: Phase III RCT in GH-deficient children; Phase II evidence for GH stimulation in adults
  FDA status: Not FDA-approved for adult use (the pediatric Geref approval was withdrawn in 2008). Sermorelin is a GHRH (1-29) analog and shares the GHRH-analog class with CJC-1295; its 503A Bulks List status has been under FDA and PCAC review as part of the broader 2023–2026 evaluation of compounded GHRH analogs. As of April 2026, sermorelin remains compounded by some 503A pharmacies pursuant to individual patient prescriptions, but its 503A pathway is under the same pressure as the other GHRH analogs covered in this article.
  SP availability: Not currently available through Superpower
  WADA status: Prohibited under Section S2.2 (Peptide hormones and their releasing factors — GHRH analogues) of the 2026 WADA Prohibited List
  Route: Subcutaneous injection
• Compound: BPC-157
  Mechanism for bodybuilding: Proposed cytoprotection and angiogenesis (VEGF, FAK-paxillin) in tendon, muscle, and connective tissue; no direct anabolic mechanism
  Evidence: Animal studies only — no human RCTs as of April 2026
  FDA status: Not FDA-approved. Removed from FDA's Category 2 list of bulk drug substances under 503A/503B consideration on April 22, 2026; outside any FDA-permissible compounding category. PCAC review remains pending separately.
  SP availability: Not currently available through Superpower
  WADA status: Not currently on the 2026 WADA Prohibited List, but under WADA monitoring
  Route: Injectable (animal studies); no established human route
• Compound: TB-500 (thymosin beta-4 fragment)
  Mechanism for bodybuilding: Proposed promotion of endothelial cell migration, angiogenesis, and tissue repair through actin-binding properties; no direct anabolic mechanism
  Evidence: Animal studies for tissue repair; early Phase 2 human clinical data suggest thymosin beta-4 may promote healing of venous stasis ulcers, with effect sizes that varied across trial arms (Guarnera et al., 2010, Annals of the New York Academy of Sciences, PMID 20536470) — not athletic recovery
  FDA status: As of April 22, 2026, thymosin beta-4 and TB-500 were removed from FDA's Category 2 list of bulk drug substances under 503A/503B consideration; thymosin beta-4 had previously been reviewed by PCAC, which recommended against Bulks List inclusion. Neither is FDA-approved for any indication, and neither is within any FDA-permissible compounding category; 503A compounding is not permitted.
  SP availability: Not currently available through Superpower
  WADA status: Thymosin beta-4 is prohibited under Section S2.5 of the 2026 WADA Prohibited List (growth factors and modulators); TB-500 as a fragment is treated as prohibited by extension
  Route: Injectable (animal studies)

Compounds listed as research-only or with restricted compounding status are not legal to prescribe in the US for bodybuilding use. Their presence in this article is for educational context only.

Peptides for Bodybuilding: Individual Profiles

Each compound below has a distinct mechanism and evidence base. The evidence for each must be evaluated separately — findings from one compound do not support claims about another.

CJC-1295 and ipamorelin: the GH secretagogue combination

CJC-1295 is a modified GHRH analog with an extended half-life; ipamorelin is a selective growth hormone-releasing peptide. Together, they provide complementary signals along the GH secretagogue pathway — CJC-1295 sustaining GHRH receptor signaling, ipamorelin providing pulsatile stimulation at ghrelin receptors on the pituitary. The compound studied in the Teichman et al. 2006 study is CJC-1295 with Drug Affinity Complex (CJC-1295-DAC), which has a half-life of approximately 8 days due to albumin binding. "CJC-1295" as referenced in compounding and grey-market contexts often refers to CJC-1295 without DAC (also called Modified GRF 1-29 or Mod-GRF 1-29), which has a half-life measured in minutes. These are pharmacokinetically distinct compounds; the effect magnitudes below apply only to the DAC version. Teichman and colleagues, in a Phase I dose-escalation study published in the Journal of Clinical Endocrinology and Metabolism in 2006, enrolled 44 healthy adults and documented CJC-1295-DAC producing 2 to 10-fold increases in mean plasma GH for 6 or more days after a single injection, with 1.5 to 3-fold IGF-1 increases persisting 9 to 11 days. [Phase I pharmacokinetic/pharmacodynamic study]

Raun and colleagues, in 1998, characterized ipamorelin as a selective GH secretagogue with minimal ACTH and cortisol stimulation — a selectivity advantage over GHRP-2 and hexarelin as characterized in the same work. Ionescu and Frohman demonstrated that short-acting CJC-1295 preserves pulsatile GH secretion relative to exogenous HGH administration, though the long-acting DAC-modified form produces a more sustained GH elevation profile.

Neither compound is FDA-approved for any adult indication. CJC-1295 and ipamorelin have historically been compounded by 503A pharmacies using bulk drug substances; however, at its April 22, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee (PCAC) recommended against including CJC-1295 and ipamorelin on the 503A Bulks List. Once FDA acts on this recommendation, 503A compounding of these peptides using bulk drug substances will no longer be available. As of Section S2 of the 2026 WADA Prohibited List, both are prohibited in and out of competition. The lean-mass evidence for this combination in healthy, resistance-trained athletes is absent — available human data is from older, GH-deficient, or metabolically compromised populations. Not currently available through Superpower.

MK-677: the oral GH secretagogue

MK-677 is technically not a peptide — it is a non-peptide small molecule that activates GH secretagogue receptors orally by mimicking ghrelin. It is discussed here because it circulates widely in bodybuilding communities alongside GH secretagogue peptides and because its human evidence base is somewhat more developed. Nass and colleagues, in a two-year randomized controlled trial in the Annals of Internal Medicine in 2008, enrolled 65 adults aged 60 to 81 and found MK-677 prevented fat-free mass decline and reduced abdominal visceral fat while also reducing insulin sensitivity. [Phase II RCT — older adult population] Svensson and colleagues, in a two-month RCT in obese subjects published in the Journal of Clinical Endocrinology and Metabolism in 1998, showed MK-677 increased fat-free mass and basal metabolic rate without significant fat mass reduction.

MK-677 is not FDA-approved for any indication. It is not a peptide — it is a small-molecule ghrelin receptor agonist. FDA has treated MK-677 as an unapproved new drug and has issued warning letters to online sellers marketing MK-677 for human use. It is not on the 503A Bulks List, and 503A compounding of MK-677 is not an authorized pathway. As of Section S2 of the 2026 WADA Prohibited List, MK-677 is prohibited. The insulin sensitivity concern documented in the MK-677 trials is clinically significant: glucose and HbA1c monitoring would be required in any clinical evaluation of GH-axis compound use. Vann and colleagues published a 2022 case report (single-subject observational data, N=1) in Experimental Physiology documenting one individual who combined MK-677 with the SARM LGD-4033; the case report reported mixed body composition changes and adverse biomarker shifts in the single subject. This is real-world case-report evidence, not a controlled study, and should not be interpreted as establishing general effects. Not currently available through Superpower.

BPC-157: the recovery compound

BPC-157 has not been approved by the FDA for any medical use. Research has been limited to animal studies; no human RCTs have been published as of April 2026. It is not available through Superpower or any licensed prescriber for bodybuilding use. Inclusion here is for educational context only. [Animal study]

Preclinical studies in rodent models have characterized BPC-157's effects on tissue repair pathways (tendon fibroblast activation, VEGF upregulation, angiogenesis). These animal findings do not establish efficacy, safety, dose, or duration in humans; no human RCTs have been published. The Daniëls and colleagues 2025 systematic review in HSS Journal, the most current assessment, acknowledged sports medicine recovery promise while noting the complete absence of human RCTs and risks from unregulated manufacturing. As of April 22, 2026, BPC-157 was removed from FDA's Category 2 list of bulk drug substances under 503A/503B consideration. Removal is not equivalent to Category 1 approval; it places BPC-157 outside any FDA-permissible compounding category, and 503A compounding using bulk drug substance is not permitted. PCAC review of BPC-157 remains pending separately.

TB-500 and thymosin beta-4

TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), an endogenous protein involved in actin binding, endothelial cell migration, and tissue repair. Goldstein and colleagues, reviewing thymosin beta-4's biological properties in Expert Opinion on Biological Therapy in 2012, described Tβ4's role in wound healing, cardiac repair, and connective tissue recovery. Guarnera and colleagues, in a 2010 paper in Annals of the New York Academy of Sciences, reported Phase 2 clinical trial data suggesting thymosin beta-4 may promote healing of venous stasis ulcers, with effect sizes that varied across trial arms — the highest-quality Tβ4 human data available, though in wound-healing rather than athletic contexts. This wound-healing data does not directly translate to athletic recovery claims. [Phase 2 clinical data for wound healing only] As of April 22, 2026, thymosin beta-4 and TB-500 were removed from FDA's Category 2 list of bulk drug substances under 503A/503B consideration; PCAC had previously recommended against inclusion of thymosin beta-4 on the 503A Bulks List. Neither is FDA-approved for any indication; neither is within any FDA-permissible compounding category; 503A compounding is not permitted. As of Section S2.5 of the 2026 WADA Prohibited List, thymosin beta-4 is prohibited, and TB-500 as a fragment is treated as prohibited by extension. Not currently available through Superpower.

Regulatory Status at a Glance

As of April 2026, the compounds discussed in this article carry different regulatory statuses. No compound discussed here is FDA-approved for bodybuilding or athletic performance enhancement.

• CJC-1295: Not FDA-approved. Historically 503A-compoundable; PCAC recommended against 503A Bulks List inclusion on April 22, 2026, so availability is actively contracting. Prohibited under Section S2 of the 2026 WADA Prohibited List.
• Ipamorelin: Not FDA-approved. Historically 503A-compoundable; PCAC recommended against 503A Bulks List inclusion on April 22, 2026, so availability is actively contracting. Prohibited under Section S2 of the 2026 WADA Prohibited List.
• Sermorelin: Not FDA-approved for adult use (the pediatric Geref approval was withdrawn in 2008). Historically compounded under Section 503A; 503A availability is under active FDA and PCAC review as part of the broader 2023–2026 GHRH-analog evaluation. Prohibited under Section S2.2 (Peptide hormones and their releasing factors) of the 2026 WADA Prohibited List.
• MK-677: Not FDA-approved for any indication. Not a peptide — a small-molecule ghrelin receptor agonist. Treated by FDA as an unapproved new drug; warning letters issued to online sellers. Not on the 503A Bulks List; 503A compounding is not an authorized pathway. Prohibited under Section S2 of the 2026 WADA Prohibited List.
• BPC-157: Not FDA-approved for any medical use. Removed from FDA's Category 2 list of bulk drug substances under 503A/503B consideration on April 22, 2026; outside any FDA-permissible compounding category; 503A compounding is not permitted. PCAC review remains pending separately. Not currently on the 2026 WADA Prohibited List but under WADA monitoring.
• TB-500 / Thymosin beta-4: Not FDA-approved for any indication. Removed from FDA's Category 2 list of bulk drug substances under 503A/503B consideration on April 22, 2026; PCAC had previously recommended against 503A Bulks List inclusion of thymosin beta-4; TB-500 as a synthetic Tβ4 fragment shares this status; outside any FDA-permissible compounding category; 503A compounding is not permitted. Thymosin beta-4 is prohibited under Section S2.5 (growth factors and modulators) of the 2026 WADA Prohibited List; TB-500 as a fragment is treated as prohibited by extension.

Substances outside any FDA-permissible compounding category — including BPC-157 and TB-500 following their April 22, 2026 removal from the Category 2 list — cannot be lawfully compounded by 503A pharmacies. USP/NF monographs for these peptides do not exist, and no FDA-registered manufacturer supplies them. Products sold online operate outside FDA manufacturing oversight.

The Federal Legal Framework Beyond WADA

Federal law imposes criminal penalties beyond the anti-doping framework. 21 U.S.C. § 333(e) makes distribution of human growth hormone (somatropin or its analogues) for any use other than treatment of an authorized medical condition a federal felony punishable by up to 5 years imprisonment (10 years if distribution is to a minor). GHRH analogs and GHRPs are pharmacologically distinct from HGH — they stimulate endogenous GH release rather than replacing it — and courts have generally not extended § 333(e) to reach secretagogues. The federal framework that applies to GHRH analogs and GHRPs distributed for human use without FDA approval is 21 U.S.C. § 331(d), which prohibits introducing any unapproved new drug into interstate commerce, coupled with the FDA intended use doctrine (21 CFR 201.128) — applicable to any peptide sold for human therapeutic use without FDA approval, including "research use only"-labeled products whose seller knows or has reason to know will be used for human administration. Purchasing these compounds from online research-chemical vendors for self-administration does not insulate either the seller or the purchaser from these frameworks. For HGH itself (somatropin), § 333(e) continues to impose a separate and more severe felony framework on distribution for non-medical purposes.

Athletes subject to anti-doping jurisdiction should verify current WADA status on the official 2026 WADA Prohibited List (wada-ama.org).

Considerations When Comparing Peptides for Bodybuilding

The bodybuilding context creates specific compliance considerations that distinguish this discussion from clinical GH-axis evaluation. The primary goal in bodybuilding — maximizing hypertrophy and minimizing body fat in healthy, trained athletes — has not been studied in any controlled trial for any peptide discussed here. All available human evidence is from older adults, GH-deficient individuals, or obese subjects. The Heuberger and colleagues 2019 review in Sports Medicine found limited peer-reviewed evidence for performance-enhancing effects of peptide hormones, alongside significant uncertainty about safety outside clinical supervision.

Sub-goal differentiation: Recovery from overuse injuries or training-related connective tissue stress is a different clinical problem from maximizing lean mass accrual. BPC-157 and TB-500 have preclinical mechanisms relevant to the former. GH secretagogues are relevant to the latter in populations with genuine GH-axis insufficiency. These are not interchangeable approaches.

Evidence population gap: The most significant limitation in this category is that all human lean-mass evidence for GH secretagogues comes from populations with age-related or pathological GH decline. Extrapolating to healthy young athletes with normal GH axis function requires assumptions the data does not support. Kraemer and Ratamess documented robust endogenous GH pulses in response to resistance exercise in trained adults — suggesting the body's own GH secretion in well-trained individuals may already be optimized by training stimulus.

Regulatory and WADA status as limiting factors: Several compounds are both FDA Category 2 (503A compounding effectively prohibited) and WADA-prohibited. This combination severely limits access and creates anti-doping risk simultaneously. A provider generally cannot lawfully prescribe a Category 2 compound through standard 503A compounding channels for any patient, and the competitive athlete cannot use it in or out of competition.

The evidence cannot be combined across compounds: BPC-157 animal data does not support claims about CJC-1295 lean-mass effects, and vice versa. Each compound requires evaluation on its own evidence record.

This is not an exhaustive list of clinical considerations. A licensed provider will evaluate full health history, current medications, and baseline lab results before recommending any compound.

Safety Considerations

GH secretagogues carry class-level risks that are dose-dependent and related to GH/IGF-1 elevation magnitude. Reducing insulin sensitivity is the most clinically relevant: documented in the two-year MK-677 RCT. Fluid retention, carpal tunnel syndrome, and joint pain are GH-axis class effects, documented in a 2012 systematic review and meta-analysis in the European Journal of Endocrinology. These effects increase with supraphysiological GH levels — the physiological pulsatility of secretagogue-driven GH release may attenuate but does not eliminate these risks.

Sigalos and Pastuszak, reviewing GH secretagogue safety and efficacy in Sexual Medicine Reviews in 2018, provided a comprehensive overview of summarizing GH secretagogue data on lean mass, fat mass, and exercise tolerance across the class, noting that most available evidence comes from specific clinical populations and that safety data for healthy athletes is lacking.

For BPC-157 and TB-500: there are no published human safety data. The sourcing risk with these compounds is compounded by their Category 2 classification — products sold online operate without pharmaceutical-grade manufacturing standards, and contamination, dosing inconsistency, and misidentification are documented concerns with gray-market injectable products generally.

Contraindications that apply broadly to this compound category include:

• Competitive athletes subject to WADA or sport governing body anti-doping rules — multiple compounds in this list are WADA-prohibited and detectable
• Active or history of hormone-sensitive malignancy — GH/IGF-1 axis stimulation carries theoretical proliferative concern
• Pre-existing insulin resistance or type 2 diabetes — GH secretagogues reduce insulin sensitivity; glucose monitoring is essential
• Pregnancy — no reproductive safety data for any compound in this category
• Pituitary adenoma or other pituitary pathology — GH-stimulating compounds are contraindicated

For compound-specific side effect profiles, see the individual compound pages linked in this article.

What to Test Before Starting Peptides for Bodybuilding

Regardless of the compound under discussion, baseline biomarker testing establishes a measurable starting point for any clinical evaluation. For compounds without a lawful US prescribing pathway — including MK-677, BPC-157, and TB-500 — the article is educational; a provider conversation about these specific compounds is not a realistic clinical option under current FDA classification.

• IGF-1: The primary downstream marker of GH axis function. A baseline IGF-1 level establishes whether there is genuine GH-axis insufficiency — a clinical rationale consistent with the populations in which FDA-approved GHRH analogs (e.g., tesamorelin for HIV-associated lipodystrophy) have been evaluated. Without this baseline, any subsequent IGF-1 change during compound use has no reference point.
• Fasting glucose and HbA1c: GH secretagogues reduce insulin sensitivity. A baseline fasting glucose and HbA1c characterize the starting insulin sensitivity state and establish the reference point for monitoring metabolic changes during any GH-axis compound.
• hs-CRP: Systemic inflammation attenuates muscle repair and satellite cell function. A baseline hs-CRP identifies whether chronic low-grade inflammation is limiting recovery capacity — relevant for contextualizing whether a tissue-repair peptide approach might address a genuine biological limitation.
• Total and free testosterone: The HPG axis contributes independently to lean mass and recovery. A full testosterone baseline at the total testosterone level distinguishes HPG-axis from GH-axis contributions to current body composition status.
• Comprehensive metabolic panel (ALT, AST, eGFR): Liver and kidney function are standard safety baselines in any clinical evaluation where GH-axis biology is under discussion. Hepatic processing considerations are relevant for orally bioavailable GH-axis compounds.
• Triglycerides and lipid panel: GH axis activity influences fat metabolism and lipid profiles. A triglyceride baseline provides context for any changes in fat metabolism during GH secretagogue use.

IGF-1, fasting glucose, HbA1c, and a comprehensive metabolic panel establish the minimum baseline before any GH-axis compound discussion. The strength and resilience biomarker guide covers these markers in the context of athletic performance and body composition.

How to Access These Peptides Safely

For GHRH analogs and GHRPs — CJC-1295, ipamorelin, and sermorelin — that have historically been compounded under Section 503A, the regulatory pathway is actively contracting. At its April 22, 2026 meeting, PCAC recommended against including CJC-1295 and ipamorelin on the 503A Bulks List; sermorelin is a GHRH analog in the same class and its 503A Bulks List status is under the same FDA and PCAC review. None of these compounds has an FDA-approved indication in adult patients. No recognized clinical practice guideline from Endocrine Society, AACE, or comparable bodies endorses GHRH-analog therapy for idiopathic age-related GH decline. Performance enhancement and bodybuilding are not recognized clinical indications. Any prescribing decision for any of these compounds is the licensed provider's sole clinical responsibility, subject to applicable state medical-board standards and federal law.

MK-677 and BPC-157 cannot currently be legally obtained through US compounding pharmacies under their Category 2 classification. Products sold online as these compounds operate without FDA manufacturing oversight — documented risks include contamination, dosing errors, and misidentified compounds. Self-directed use without provider oversight creates pharmacological and sourcing risks that cannot be managed without professional involvement.

For competitive athletes: confirming WADA or sport-governing-body prohibited status before beginning any compound is the athlete's responsibility. Several compounds in this article are prohibited in and out of competition.

Understanding Your Baseline

For bodybuilding specifically, the most clinically grounded entry point is the question: "Is there a measurable biological limitation that a specific compound could address?" That question cannot be answered without baseline data. An IGF-1 level in the lower quartile for age and sex, combined with suboptimal body composition despite consistent training and adequate nutrition, presents a different clinical picture than normal-range IGF-1 in a well-trained athlete — and those two scenarios would lead a provider to different compound discussions, if any.

That principle — test first, then decide — is central to Superpower's approach to preventive health. Whether the conversation with your provider leads to a GH secretagogue protocol, a nutritional optimization, or a broader hormonal evaluation, the starting point is the same: knowing where your biomarkers stand.

IMPORTANT SAFETY INFORMATION

No compound discussed in this article is FDA-approved for bodybuilding or athletic performance enhancement. The use of these compounds in non-clinical bodybuilding contexts is not supported by adequate human clinical trial evidence.

CJC-1295 and ipamorelin are not FDA-approved for any indication. Historically, CJC-1295 and ipamorelin have been compounded by 503A pharmacies pursuant to individual patient prescriptions, primarily in anti-aging and functional-medicine practice settings. These compounds have no FDA-approved indication, and age-related GH decline (somatopause) is not an FDA-recognized clinical indication; major endocrine society guidelines (Endocrine Society, AACE) do not endorse GHRH-analog therapy for idiopathic age-related GH decline. Following the April 22, 2026 PCAC recommendation against 503A Bulks List inclusion, this pathway is contracting. Bodybuilding and athletic performance are not recognized clinical indications, and no licensed provider can lawfully prescribe these compounds for performance enhancement. As of Section S2 of the 2026 WADA Prohibited List, GH-releasing peptides including ipamorelin are prohibited substances in and out of competition. Human safety data for use in healthy athletes does not exist. Superpower does not currently offer, prescribe, compound, or facilitate access to CJC-1295 or ipamorelin for any indication.

Sermorelin is not FDA-approved for adult use (the pediatric Geref approval was withdrawn in 2008). Sermorelin is a GHRH analog compounded under Section 503A pursuant to individual patient prescriptions; its 503A pathway is under active FDA and PCAC review as part of the broader 2023–2026 evaluation of compounded GHRH analogs. Its pediatric GH deficiency efficacy trials do not establish efficacy for adult bodybuilding purposes. As of Section S2.2 (Peptide hormones and their releasing factors) of the 2026 WADA Prohibited List, sermorelin is prohibited. Superpower does not currently offer, prescribe, compound, or facilitate access to sermorelin for any indication.

MK-677 is not FDA-approved for any indication and is not a peptide — it is a small-molecule ghrelin receptor agonist. FDA has treated MK-677 as an unapproved new drug and has issued warning letters to online sellers marketing it for human use. It is not on the 503A Bulks List, and 503A compounding of MK-677 is not an authorized pathway. As of Section S2 of the 2026 WADA Prohibited List, MK-677 is prohibited. Documented adverse effects include reduced insulin sensitivity over two years in older adults — glucose monitoring is clinically required. Superpower does not currently offer, prescribe, compound, or facilitate access to MK-677 for any indication.

BPC-157 is not approved by the FDA for any medical use. Research is limited to animal studies. Safety, efficacy, dosing, and long-term effects in humans have not been established. As of April 22, 2026, FDA removed BPC-157 from the Category 2 list of bulk drug substances under 503A/503B consideration; BPC-157 is outside any FDA-permissible compounding category, is not eligible for 503A compounding, and is not legally available through US licensed prescribers. PCAC review remains pending separately. BPC-157 is not prescribed, compounded, or dispensed through Superpower for any indication.

Thymosin beta-4 / TB-500 is not FDA-approved for any indication. As of April 22, 2026, thymosin beta-4 and TB-500 were removed from FDA's Category 2 list of bulk drug substances under 503A/503B consideration; PCAC had previously recommended against Bulks List inclusion of thymosin beta-4. Both are outside any FDA-permissible compounding category; 503A compounding is not permitted. As of Section S2.5 of the 2026 WADA Prohibited List, thymosin beta-4 is a prohibited substance; TB-500 as a fragment is treated as prohibited by extension. Phase 2 human data exists for wound healing only; athletic recovery claims are not supported by human clinical evidence. TB-500 is not prescribed, compounded, or dispensed through Superpower for any indication.

Federal law imposes criminal penalties beyond the anti-doping framework. 21 U.S.C. § 333(e) makes distribution of human growth hormone (somatropin) for any use other than treatment of an authorized medical condition a federal felony. 21 U.S.C. § 331(d) prohibits introducing unapproved new drugs into interstate commerce, and it is the primary federal criminal provision that applies to GHRH analogs, GHRPs, and other peptides sold for human therapeutic use without FDA approval.

Adverse effects reported in the GH secretagogue class literature include fluid retention, reduced insulin sensitivity, carpal tunnel syndrome, joint pain, and (for compounds acting at ghrelin receptors) increased appetite. Secretagogue-driven pulsatile GH release may attenuate but does not eliminate these risks. No systematic human adverse event profile has been published for BPC-157 or TB-500.

Full FDA-approved prescribing information at dailymed.nlm.nih.gov.

Disclaimer: This article discusses multiple peptide compounds with different regulatory statuses. Some compounds are available through compounding pharmacies; some are not approved for human use. No compound discussed is FDA-approved for bodybuilding or athletic performance enhancement. Superpower Health does not offer these compounds for bodybuilding use. This educational content is editorially independent.